BioRegenx, Inc. Stock Price

BioRegenx, Inc. develops, manufactures, and sells medical test equipment and science-based nutritional products in the United States and internationally. The company offers Endocalyx Pro, a dietary supplement targeting microvascular capillary health and a range of other supplements under the MyBodyRx brand name; GlycoCheck software; and other health and wellness devices, such as pulsed electro-magnetic field devices, as well as StimaWELL and ReLounge, an electronic muscle stimulation therapy device; and markets hydrogen water products. It also develops TruScan.Ai mobile app/website that integrates additional health indicators; and VitalWellness app, which merge its DNA and epigenetics platform. In addition, the company operates a social media content management platform, including its interactive search engine. Further, it provides DocSun Artificial Intelligence (AI) Engine, which integrates advanced ballistocardiography that detects an individual's heartbeat without touch; photoplethysmography, a method that uses light to track the flow of blood; and distributes wellness devices. The company sells its products through a direct selling channel to health professionals and research organizations. BioRegenx, Inc. is headquartered in Chattanooga, Tennessee.